Pri-724

Hepatitis B

Kiminori Kimura, MDPhase 1/2Dormant

CCC

50/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 89/ 100

Competitive context

23 Active assets in the Hepatitis B cohort.

Asset / Sponsor	Phase	Rating
Entecavir Sun Yat-sen University	Phase 4	BBB
Lamivudine Fudan University	Phase 4	BBB
tenofovir Ruijin Hospital	Phase 4	BB
Hepatitis B Virus Vaccine Eunice Dube	Phase 4	BB
TENOFOVIR BIS(ISOPROPYLOXYCARBONYLOXYMETHYL) ESTER West China Hospital	Phase 4	BB

View all 45 →

Same molecule, other indications

Pri-724 is also rated in:

cirrhosis of liverDormant

BB

Indicative ·

69 / 100

colorectal cancerDormant

CCC

Indicative ·

53 / 100

hepatitis C virus infectionDormant

CCC

Indicative ·

52 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.